1 / 3

European genomics biomarker market Size, Share, Trends & Forecast 2019-2025

The European genomics biomarker market is estimated to grow significantly at a CAGR of more than 14% during the forecast period.

DIGITALG9
Télécharger la présentation

European genomics biomarker market Size, Share, Trends & Forecast 2019-2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European genomics biomarker market Size, share, Industry Growth, Future Prospects, Opportunities, Forecast 2019-2025 European genomics biomarker market Size, Share, Trends & Forecast 2019-2025 European genomics biomarker market Size, Share and Forecast 2019-2025 The European genomics biomarker market is estimated to grow significantly at a CAGR of more than 14% during the forecast period. Factors that are contributing significantly to the market growth include the presence of a well-developed healthcare sector and considerably high healthcare expenditure and infrastructure in its economies such as Germany, UK, France, and others. Other factors contributing to the European genomics biomarker market include the rising prevalence of chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in European countries are the major factors for increasing cancer incidences among men and women. Government initiatives, programs, and funding related to increasing awareness of cancer are also contributing to the growth of the market in the region. Request a Free Sample of our Report on European genomics biomarker: https://www.omrglobal.com/request-sample/european-genomic-biomarkers- market The European genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. On the basis of end-user, the market is segmented into hospitals and diagnostic. Further, the report covers the country-level analysis of the genomics biomarker market in Europe. The major economies covered in the report include UK, Germany, Italy, Spain, France, and the Rest of Europe. The rest of Europe is estimated to hold a significant share in the market owing to the increasing healthcare spending in countries such as the Netherlands and Poland. As a result, it is primarily contributing to the adoption of advanced biomarkers for screening and detection of disease and thereby enabling the demand for genomic biomarkers. Moreover, Germany, UK, and Spain are estimated to grow at a considerable CAGR during the forecast period. The significant prevalence of CVD and cancer is expected to propel the adoption of the genomic biomarker in these countries. A full Report of European genomics biomarker market is Available at: https://www.omrglobal.com/industry-reports/european-genomic-biomarkers- market

  2. Some of the major players in the European genomic biomarker market include F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., Qiagen NV, Novartis AG, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, investments in R&D, and merger and acquisition. For instance, in April 2018, BioMérieux S.A. completed its acquisition of Astute Medical for around $90 million. Under this agreement, the company was given access to promising biomarkers in the product pipeline of Astute Medical. Market Segmentation European Genomic Biomarker Market by Application  Oncology  Cardiology  Neurology  Others European Genomic Biomarker Market by End-User  Hospitals  Diagnostic & Research Laboratories Regional Analysis  UK  Germany  Italy  Spain  France  Rest of Europe Company Profiles  Acobiom SAS  Agendia N.V.  Agilent Technologies, Inc.

  3.  Avacta Group Plc  Bayer AG  BioMérieux S.A.  BioPorto Diagnostics A/S  Bio-Rad Laboratories, Inc.  DestiNA Genomics Ltd.  DNAVision SA  Eagle Genomics Ltd.  Epigenomics AG  Epistem Ltd  Eurofins Scientific SE For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-genomic-biomarkers- market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 780-304-0404

More Related